Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 22:12:586893.
doi: 10.3389/fphar.2021.586893. eCollection 2021.

ICU Patients' Antibiotic Exposure and Triazole-Resistance in Invasive Candidiasis: Parallel Analysis of Aggregated and Individual Data

Yan Wang  1   2   3 , Ying Zhang  2 , Treasure M McGuire  3   4   5 , Samantha A Hollingworth  3 , Mieke L Van Driel  6 , Lu Cao  7 , Xue Wang  8 , Yalin Dong  2
Affiliations

ICU Patients' Antibiotic Exposure and Triazole-Resistance in Invasive Candidiasis: Parallel Analysis of Aggregated and Individual Data

Yan Wang et al. Front Pharmacol. .

Abstract

Background: The relationship between antibiotic use and the incidence of triazole-resistant phenotypes of invasive candidiasis (IC) in critically ill patients is unclear. Different methodologies on determining this relationship may yield different results. Methods: A retrospective multicenter observational analysis was conducted to investigate exposure to antibiotics and the incidence of non-duplicate clinical isolates of Candida spp. resistant to fluconazole, voriconazole, or both during November 2013 to April 2018, using two different methodologies: group-level (time-series analysis) and individual-patient-level (regression analysis and propensity-score adjusting). Results: Of 393 identified Candida spp. from 388 critically ill patients, there were three phenotypes of IC identified: fluconazole-resistance (FR, 63, 16.0%); voriconazole-resistance (VR, 46, 11.7%); and cross-resistance between fluconazole and voriconazole (CR, 32, 8.1%). Exposure to several antibacterial agents with activity against the anaerobic gastrointestinal flora, especially third-generation cefalosporins (mainly cefoperazone/sulbactam and ceftriaxone), but not triazoles, have an immediate effect (time lag = 0) on subsequent ICU-acquired triazole-resistant IC in the group-level (p < 0.05). When the same patient database was analyzed at the individual-patient-level, we found that exposure to many antifungal agents was significantly associated with triazole-resistance (fluconazole [adjusted odds ratio (aOR) = 2.73] or caspofungin [aOR = 11.32] on FR, voriconazole [aOR = 2.87] on CR). Compared to the mono-triazole-resistant phenotype, CR IC has worse clinical outcomes (14-days mortality) and a higher level of resistance. Conclusion: Group-level and individual-patient-level analyses of antibiotic-use-versus-resistance relations yielded distinct but valuable results. Antibacterials with antianaerobic activity and antifungals might have "indirect" and "direct" effect on triazole-resistant IC, respectively.

Keywords: critical illness; drug resistance; fungal; invasive candidiasis; regression analysis; time series analysis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Monthly incidence of non-duplicate triazole-resistant isolates and antibiotic consumption per 100 patient-days (A) Fluconazole-resistant invasive candidiasis (B) Voriconazole-resistant invasive candidiasis (C) Cross-resistant invasive candidiasis. The number on the x-axis are months (from November 2013 to April 2018).
FIGURE 2
FIGURE 2
Cumulative survival in patients with cross-resistant, mono-triazole-resistant, and non-resistant invasive candidiasis using Kaplan-Meier curves. The dashed line indicates the 95% confidence interval: yellow for non-resistant; green for mono-triazole-resistant; red for cross-resistant invasive candidiasis.
See this image and copyright information in PMC

References

    1. Bailly S., Maubon D., Fournier P., Pelloux H., Schwebel C., Chapuis C., et al. (2016). Impact of antifungal prescription on relative distribution and susceptibility of candida spp.—trends over 10 years. J. Infect. 72, 103–111. 10.1016/j.jinf.2015.09.041 - DOI - PubMed
    1. Ben-Ami R., Olshtain-Pops K., Krieger M., Oren I., Bishara J., Dan M., et al. (2012). Antibiotic exposure as a risk factor for fluconazole-resistant candida bloodstream infection. Antimicrob. Agents Chemother. 56, 2518–2523. 10.1128/AAC.05947-11 - DOI - PMC - PubMed
    1. Burton D. C., Edwards J. R., Horan T. C., Jernigan J. A., Fridkin S. K. (2009). Methicillin-resistant staphylococcus aureus central line-associated bloodstream infections in us intensive care units, 1997-2007. JAMA 301, 727–736. 10.1001/jama.2009.153 - DOI - PubMed
    1. Calandra T., Roberts J. A., Antonelli M., Bassetti M., Vincent J. L. (2016). Diagnosis and management of invasive candidiasis in the icu: an updated approach to an old enemy. Crit. Care 20, 125. 10.1186/s13054-016-1313-6 - DOI - PMC - PubMed
    1. de Micheli M., Bille J., Schueller C., Sanglard D. (2002). A common drug-responsive element mediates the upregulation of the candida albicans abc transporters cdr1 and cdr2, two genes involved in antifungal drug resistance. Mol. Microbiol. 43, 1197–1214. 10.1046/j.1365-2958.2002.02814.x - DOI - PubMed

LinkOut - more resources